

# Xavier Montalban

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2441763/publications.pdf>

Version: 2024-02-01

454  
papers

51,475  
citations

3525

90  
h-index

1751

212  
g-index

488  
all docs

488  
docs citations

488  
times ranked

32006  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España. <i>Neurología</i> , 2022, 37, 615-630.	0.3	3
2	Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 173-182.	1.4	8
3	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2022, 29, 1075-1081.	1.7	16
4	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2022, 28, 71-81.	1.4	10
5	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2022, 29, 1082-1090.	1.7	11
6	A smartphone sensor-based digital outcome assessment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 654-664.	1.4	51
7	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 608-619.	1.4	13
8	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2022, 269, 452-459.	1.8	10
9	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 910-924.	1.4	27
10	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.5	31
11	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103385.	0.9	8
12	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 950-957.	1.4	7
13	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103389.	0.9	6
14	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1209-1218.	1.4	4
15	Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2022, 28, 16-28.	1.4	5
16	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1131-1137.	1.4	13
17	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1277-1285.	1.4	12
18	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. <i>Journal of Neurology</i> , 2022, 269, 1764-1772.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, e1143.	3.1	17
20	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. <i>NeuroImage: Clinical</i> , 2022, 34, 102967.	1.4	13
21	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. <i>Neurology and Therapy</i> , 2022, 11, 741-758.	1.4	18
22	Can Cognitive training Reignite Compensatory Mechanisms in Advanced Multiple Sclerosis Patients? An Explorative Morphological Network Approach. <i>Neuroscience</i> , 2022, , .	1.1	0
23	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1562-1575.	1.4	25
24	SWI as an Alternative to Contrast-Enhanced Imaging to Detect Acute MS Lesions. <i>American Journal of Neuroradiology</i> , 2022, 43, 534-539.	1.2	2
25	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2022, 28, 842-846.	1.4	13
26	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022, 2, 100071.	2.8	1
27	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 732-740.	0.9	8
28	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1138-1145.	1.4	11
29	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving nonâ€œcellâ€œautonomous neuronal damage. <i>Clinical and Translational Medicine</i> , 2022, 12, e837.	1.7	4
30	Two years of COVID-19 in the MS community: What have we learnt so far?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1005-1008.	1.4	3
31	Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis. <i>Neurology</i> , 2022, 99, .	1.5	6
32	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€œyears of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	1.4	16
33	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	15
34	Adding brain volume measures into response criteria in multiple sclerosis: the RÃœ-4 score. <i>Neuroradiology</i> , 2021, 63, 1031-1041.	1.1	2
35	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021, 27, 479-482.	1.4	7
36	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021, 89, 13-23.	2.8	123

#	ARTICLE	IF	CITATIONS
37	Innovation in resident education – Description of the Neurology International Residents Videoconference and Exchange (NIRVE) program. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117222.	0.3	7
38	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	0.9	20
39	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	35
40	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021, 28, 3384-3395.	1.7	111
41	U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. <i>Gait and Posture</i> , 2021, 84, 120-126.	0.6	19
42	Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries. <i>Multiple Sclerosis Journal</i> , 2021, 27, 90-96.	1.4	5
43	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	19
44	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021, 27, 913-921.	1.4	20
45	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. <i>JAMA Neurology</i> , 2021, 78, 351.	4.5	30
46	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. <i>Neurotherapeutics</i> , 2021, 18, 920-937.	2.1	18
47	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	12
48	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021, 28, 2533-2542.	1.7	16
49	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	1.7	33
50	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. <i>JAMA Neurology</i> , 2021, 78, 558.	4.5	132
51	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
52	Targeting Inflammasomes to Treat Neurological Diseases. <i>Annals of Neurology</i> , 2021, 90, 177-188.	2.8	46
53	Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1065.	3.1	1
54	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. <i>European Journal of Neurology</i> , 2021, 28, 4124-4134.	1.7	4

#	ARTICLE	IF	CITATIONS
55	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology, The</i> , 2021, 20, 653-670.	4.9	302
56	Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. <i>Autoimmunity Reviews</i> , 2021, 20, 102893.	2.5	41
57	CSF Chitinase 3â€“Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	15
58	Developing a Digital Solution for Remote Assessment in Multiple Sclerosis: From Concept to Software as a Medical Device. <i>Brain Sciences</i> , 2021, 11, 1247.	1.1	16
59	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021, 97, e1641-e1652.	1.5	35
60	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1546-e1559.	1.5	75
61	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2021, 20, 729-738.	4.9	89
62	Optic Nerve Topography in Multiple Sclerosis Diagnosis. <i>Neurology</i> , 2021, 96, e482-e490.	1.5	32
63	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. <i>Frontiers in Immunology</i> , 2021, 12, 760546.	2.2	3
64	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55â€“IL6ST Gene Region in Immature Dendritic Cells. <i>Frontiers in Immunology</i> , 2021, 12, 816930.	2.2	6
65	Immunomodulatory Effects Associated with Cladribine Treatment. <i>Cells</i> , 2021, 10, 3488.	1.8	14
66	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 912-923.	1.4	52
67	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1074-1082.	1.4	5
68	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1658-1669.	1.4	41
69	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020, 19, 102429.	2.5	197
70	CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1121-1124.	1.4	13
71	Modelling multiple sclerosis using induced pluripotent stem cells. <i>Journal of Neuroimmunology</i> , 2020, 349, 577425.	1.1	7
72	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	1.1	9

#	ARTICLE	IF	CITATIONS
73	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	4.9	64
74	Five years of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2020, 95, e1854-e1867.	1.5	81
75	Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis. <i>Neurotherapeutics</i> , 2020, 17, 1988-2003.	2.1	7
76	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). <i>Frontiers in Neurology</i> , 2020, 11, 632.	1.1	52
77	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1163-1171.	1.4	63
78	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
79	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020, 143, 2637-2652.	3.7	56
80	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 998-1009.	4.9	98
81	Multiple sclerosis and nutrition: back to the future?. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	1.5	2
82	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852098014.	1.4	3
83	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102572.	0.9	36
84	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 461-463.	1.2	27
85	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 437-455.	0.3	63
86	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
87	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
88	Radiologically Isolated Syndrome: <sc>10â€Year</sc> Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417.	2.8	95
89	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1153-1156.	1.4	24
90	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020, 41, 1308-1320.	1.1	1

#	ARTICLE	IF	CITATIONS
91	Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. <i>European Journal of Neurology</i> , 2020, 27, 2225-2232.	1.7	20
92	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	1.5	23
93	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.5	28
94	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020, 41, 1647-1650.	0.9	48
95	Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101973.	0.9	3
96	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020, 16, 171-182.	4.9	150
97	A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells. <i>Journal of Clinical Medicine</i> , 2020, 9, 625.	1.0	5
98	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	4.9	207
99	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	1.8	1
100	Biosensors to monitor MS activity. <i>Multiple Sclerosis Journal</i> , 2020, 26, 605-608.	1.4	8
101	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. <i>Scientific Reports</i> , 2020, 10, 7118.	1.6	27
102	A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. <i>Cells</i> , 2020, 9, 906.	1.8	31
103	A validation study of manual atrophy measures in patients with Multiple Sclerosis. <i>Neuroradiology</i> , 2020, 62, 955-964.	1.1	10
104	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020, 143, 1414-1430.	3.7	92
105	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732090795.	0.5	4
106	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. <i>Neurology</i> , 2020, 94, e1950-e1960.	1.5	45
107	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020, 267, 2851-2864.	1.8	8
108	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020, 43, 635-643.	1.4	20

#	ARTICLE	IF	CITATIONS
109	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
110	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 1001-1008.	1.2	68
111	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	1.4	37
112	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1535-1538.	1.4	5
113	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1446.	4.5	119
114	Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care. <i>MDM Policy and Practice</i> , 2019, 4, 238146831985564.	0.5	6
115	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2019, 18, 845-856.	4.9	110
116	Head-to-head drug comparisons in multiple sclerosis. <i>Neurology</i> , 2019, 93, 793-809.	1.5	20
117	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. <i>Neurology</i> , 2019, 93, e1852-e1866.	1.5	37
118	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	4.9	191
119	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	4.9	184
120	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	0.5	34
121	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019, 365, .	6.0	710
122	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
123	Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1690-1691.	1.4	7
124	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2019, 380, 2406-2417.	13.9	219
125	The Central Vein Sign in Radiologically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , 2019, 40, 776-783.	1.2	41
126	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. <i>Neuroradiology</i> , 2019, 61, 667-674.	1.1	15



#	ARTICLE	IF	CITATIONS
127	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019, 92, e1507-e1516.	1.5	49
128	Does attendance at theECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731983522.	0.5	3
129	Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2019, 15, 287-300.	4.9	167
130	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1182-1193.	1.8	61
131	Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing/remitting multiple sclerosis in a real-world clinical setting: PROTEC. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988719.	0.5	12
132	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019, 13, 1361-1374.	1.1	27
133	Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions. <i>American Journal of Pathology</i> , 2019, 189, 665-676.	1.9	19
134	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019, 92, 296-298.	1.5	15
135	Unraveling treatment response in multiple sclerosis. <i>Neurology</i> , 2019, 92, 180-192.	1.5	88
136	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	1.1	22
137	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 157-167.	0.9	94
138	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	1.4	90
139	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	1.4	9
140	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e14863.	2.1	90
141	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1383-1385.	1.4	8
142	The role of the cerebellum in multiple sclerosis 150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 89, 85-98.	2.9	48
143	Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night. <i>Multiple Sclerosis Journal</i> , 2018, 24, 558-562.	1.4	5
144	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018, 141, 1075-1084.	3.7	98

#	ARTICLE	IF	CITATIONS
145	Quantitative spinal cord MRI in radiologically isolated syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e436.	3.1	39
146	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS – No. <i>Multiple Sclerosis Journal</i> , 2018, 24, 123-125.	1.4	6
147	Classic Block Design –Pseudo–Resting–State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 313-319.	1.0	14
148	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
149	<sc>ECTRIMS</sc>/<sc>EAN</sc> guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	1.7	147
150	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	1.4	458
151	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018, 39, 399-404.	1.2	17
152	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 133-142.	4.9	98
153	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
154	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the <sc>INFORMS</sc> study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 346-356.	1.7	17
155	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	6.3	684
156	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	4.9	238
157	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018, 24, 721-727.	1.4	6
158	Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation. <i>Brain, Behavior, and Immunity</i> , 2018, 68, 1-10.	2.0	24
159	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	1.4	101
160	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018, 24, 301-312.	1.4	79
161	Disability progression markers over 6 –12 –years in interferon- $\beta$ -treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 322-330.	1.4	60
162	Varicella-zoster meningovascularitis in a multiple sclerosis patient treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2018, 24, 358-360.	1.4	17

#	ARTICLE	IF	CITATIONS
163	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 316-318.	0.9	18
164	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. <i>Journal of Neurology</i> , 2018, 265, 24-31.	1.8	11
165	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1485-1498.	1.4	19
166	Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 165-174.	2.5	82
167	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1507-1510.	1.4	11
168	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 67-84.	1.0	39
169	040â€¦An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A17.1-A17.	0.9	1
170	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1862-1870.	1.4	41
171	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1362-1371.	1.7	20
172	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018, 15, 296.	3.1	7
173	Multiple sclerosis: clinical aspects. <i>Current Opinion in Neurology</i> , 2018, 31, 752-759.	1.8	324
174	Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. <i>Frontiers in Neurology</i> , 2018, 9, 781.	1.1	16
175	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
176	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018, 15, 265.	3.1	25
177	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018, 84, 527-536.	2.8	42
178	Ocrelizumab: a new milestone in multiple sclerosis therapy. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641877302.	1.5	90
179	044â€¦Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A18.2-A19.	0.9	0
180	067â€¦Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A27.2-A28.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018, 25, 1189-1191.	1.7	53
182	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018, 9, 522.	1.1	3
183	Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018, 9, 174.	1.1	36
184	Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. <i>CNS Drugs</i> , 2018, 32, 637-651.	2.7	12
185	Cladribine tablets added to IFN- $\beta$ in active relapsing MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e477.	3.1	52
186	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. <i>Neurology</i> , 2018, 91, 622-624.	1.5	9
187	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	1.4	77
188	THUR 178...Infections during grade 3/4 lymphopenia with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A23.3-A24.	0.9	0
189	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	0.9	28
190	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 303, 62-65.	1.1	16
191	Treatment decisions in multiple sclerosis " insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017, 13, 105-118.	4.9	154
192	Metabolomic signatures associated with disease severity in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e321.	3.1	89
193	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 1692-1694.	13.9	50
194	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1486-1493.	1.2	12
195	Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor. <i>Neurotherapeutics</i> , 2017, 14, 1095-1106.	2.1	14
196	Sodium intake and multiple sclerosis activity and progression in <sc>BENEFIT</sc>. <i>Annals of Neurology</i> , 2017, 82, 20-29.	2.8	80
197	Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 195-204.	0.5	51
198	Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. <i>Scientific Reports</i> , 2017, 7, 44377.	1.6	40

#	ARTICLE	IF	CITATIONS
199	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
200	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
201	Progressive MS trials: Lessons learned. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1583-1592.	1.4	17
202	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. <i>Scientific Reports</i> , 2017, 7, 13544.	1.6	10
203	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812.	4.9	397
204	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017, 89, 1584-1593.	1.5	65
205	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017, 82, 186-195.	2.8	14
206	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. <i>Stem Cell Research</i> , 2017, 24, 155-159.	0.3	10
207	Lesion topographies in multiple sclerosis diagnosis. <i>Neurology</i> , 2017, 89, 2351-2356.	1.5	27
208	Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. <i>European Radiology</i> , 2017, 27, 1361-1368.	2.3	5
209	Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2017, 54, 4820-4831.	1.9	28
210	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017, 23, 556-566.	1.4	21
211	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2017, 38, 250-256.	1.2	9
212	Decreased soluble IFN- $\gamma$ receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017, 23, 937-945.	1.4	12
213	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. <i>Frontiers in Neurology</i> , 2017, 8, 430.	1.1	16
214	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017, 12, e0170395.	1.1	34
215	Laquinimod Safety Profile. <i>International Journal of MS Care</i> , 2017, 19, 16-24.	0.4	15
216	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 1089.	4.5	92

#	ARTICLE	IF	CITATIONS
217	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	0.9	228
218	Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 to treat analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 204-212.	0.9	31
219	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	0.8	13
220	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1386-1396.	1.4	118
221	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	3.1	134
222	Novel Insights into the Multiple Sclerosis Risk Gene <i>&lt;i&gt;ANKRD55&lt;/i&gt;</i> . <i>Journal of Immunology</i> , 2016, 196, 4553-4565.	0.4	21
223	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	1.8	112
224	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016, 87, 1076-1084.	1.5	85
225	Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2016, 286, 50-60.	2.0	21
226	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016, 87, 978-987.	1.5	109
227	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016, 87, 1368-1374.	1.5	42
228	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016, 16, 117.	0.8	40
229	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016, 92, 333-335.	3.8	24
230	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016, 1, .	1.1	3
231	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. <i>American Journal of Neuroradiology</i> , 2016, 37, 1816-1823.	1.2	30
232	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016, 134, 281-294.	2.1	36
233	Assessing response to interferon- $\beta$ in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016, 87, 134-140.	1.5	98
234	Brain Volume Loss During the First Year of Interferon- $\beta$ Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016, 26, 532-538.	1.0	21

#	ARTICLE	IF	CITATIONS
235	Precision medicine in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 254-262.	1.8	51
236	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , The, 2016, 15, 292-303.	4.9	679
237	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016, 25, 308-316.	1.4	31
238	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2016, 387, 1075-1084.	6.3	379
239	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. <i>Multiple Sclerosis Journal</i> , 2016, 22, 842-846.	1.4	18
240	Cytokine profiles show heterogeneity of interferon- $\gamma$ response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	3.1	34
241	Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design. <i>Clinical Immunology</i> , 2016, 163, 22-33.	1.4	30
242	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 318-328.	2.5	28
243	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1048-1060.	1.4	62
244	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 468-475.	0.9	137
245	Effects of diazoxide in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e147.	3.1	8
246	Pharmacogenomic study in patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e154.	3.1	19
247	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0134414.	1.1	5
248	Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , 2015, 21, 660-661.	1.4	0
249	Treating relapsing and remitting multiple sclerosis: therapy effects on brain atrophy. <i>Journal of Neurology</i> , 2015, 262, 2617-2626.	1.8	34
250	A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1332-1343.	1.4	18
251	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1802-1810.	1.4	10
252	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.5	110

#	ARTICLE	IF	CITATIONS
253	Cognitive reserve in multiple sclerosis: Protective effects of education. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1312-1321.	1.4	60
254	Predictive value of early brain atrophy on response in patients treated with interferon $\beta$ 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e132.	3.1	28
255	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. <i>NeuroImage: Clinical</i> , 2015, 9, 640-647.	1.4	31
256	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015, 138, 632-643.	3.7	54
257	Cell-specific effects in different immune subsets associated with <i>SOCS1</i> genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1498-1512.	1.4	8
258	Lipid-specific immunoglobulin G bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	2.8	48
259	NLRP3 inflammasome is associated with the response to IFN- $\beta$ 2 in patients with multiple sclerosis. <i>Brain</i> , 2015, 138, 644-652.	3.7	93
260	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. <i>Clinical Immunology</i> , 2015, 160, 133-141.	1.4	6
261	Commentary on Pique et al.'s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo's concentric sclerosis lesion. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1084-1086.	1.4	1
262	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015, 11, 471-482.	4.9	354
263	A functional variant that affects exon-skipping and protein expression of <i>SP140</i> as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015, 24, 5619-5627.	1.4	43
264	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015, 138, 918-931.	3.7	147
265	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015, 278, 277-279.	1.1	15
266	ATON: Results from a Phase II randomized trial of the B-cell-targeting agent ataccept in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 174-178.	0.3	71
267	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015, 138, 1863-1874.	3.7	403
268	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 48.	3.1	26
269	Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2015, 262, 2627-2634.	1.8	16
270	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	1.5	34



#	ARTICLE	IF	CITATIONS
271	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015, 85, 1694-1701.	1.5	55
272	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1876-1878.	1.4	2
273	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€™ establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015, 11, 597-606.	4.9	422
274	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. <i>Journal of Neuroimmunology</i> , 2015, 289, 12-20.	1.1	10
275	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015, 288, 98-101.	1.1	12
276	Interferon-beta affects mitochondrial activity in CD4<sup>+</sup> lymphocytes: Implications for mechanism of action in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1262-1270.	1.4	10
277	A new cognitive rehabilitation programme for patients with multiple sclerosis: the â€™MS-line! Projectâ€™. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1344-1348.	1.4	3
278	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015, 262, 326-336.	1.8	20
279	Myeloid-Derived Suppressor Cells are Generated during Retroviral Transduction of Murine Bone Marrow. <i>Cell Transplantation</i> , 2014, 23, 73-85.	1.2	13
280	Secondary Progression is Not the Only Explanation. <i>Acta Medica Portuguesa</i> , 2014, 27, 393-396.	0.2	3
281	MS disease activity in RESTORE. <i>Neurology</i> , 2014, 82, 1491-1498.	1.5	166
282	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014, 20, 234-242.	1.4	19
283	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e47.	3.1	11
284	DNA Vaccination Techniques. <i>Methods in Molecular Biology</i> , 2014, 1304, 39-50.	0.4	2
285	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 851-858.	0.9	101
286	Ancient and Recent Selective Pressures Shaped Genetic Diversity at AIM2-Like Nucleic Acid Sensors. <i>Genome Biology and Evolution</i> , 2014, 6, 830-845.	1.1	28
287	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 2338-2343.	1.8	52
288	Validation of semaphorin 7A and ala-Î²-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 181.	3.1	28

#	ARTICLE	IF	CITATIONS
289	Comment on "Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?" <sup>TM</sup> Maillart et al.. Multiple Sclerosis Journal, 2014, 20, 510-511.	1.4	0
290	Evaluating the response to glatiramer acetate in relapsing/remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	1.4	36
291	Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	5
292	NMO spectrum disorders: how wide is the spectrum?. Multiple Sclerosis Journal, 2014, 20, 1417-1419.	1.4	2
293	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. Journal of Neuroinflammation, 2014, 11, 46.	3.1	100
294	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 56-59.	1.1	7
295	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, 2014, 20, 272-282.	15.2	141
296	Pregnancy, sex and hormonal factors in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 527-536.	1.4	69
297	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 1721-1726.	1.4	31
298	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. Journal of Neuroimmunology, 2014, 272, 51-55.	1.1	8
299	Novel triggers, treatment targets and brain atrophy measures. Nature Reviews Neurology, 2014, 10, 72-73.	4.9	3
300	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurology, 2014, 71, 306.	4.5	402
301	Body fluid biomarkers in multiple sclerosis. Lancet Neurology, The, 2014, 13, 113-126.	4.9	204
302	Comment on: "Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients" <sup>TM</sup> . Multiple Sclerosis Journal, 2014, 20, 897-898.	1.4	0
303	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- $\beta$ therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	1.5	19
304	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology, 2014, 1, 605-617.	1.7	44
305	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. Autoimmunity, 2014, 47, 127-133.	1.2	17
306	Diagnosis and trials of clinically isolated syndrome. Lancet Neurology, The, 2014, 13, 962-963.	4.9	3

#	ARTICLE	IF	CITATIONS
307	Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene. <i>American Journal of Pathology</i> , 2014, 184, 2420-2429.	1.9	8
308	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1471-1477.	1.4	25
309	Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis. <i>CNS Drugs</i> , 2014, 28, 641-648.	2.7	24
310	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
311	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014, 271, 49-52.	1.1	2
312	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology</i> , The, 2014, 13, 472-481.	4.9	83
313	Immunoglobulin <sc>M</sc> oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014, 76, 231-240.	2.8	51
314	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509.	1.1	254
315	Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis. <i>PLoS ONE</i> , 2014, 9, e105737.	1.1	38
316	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2016-2022.	1.8	63
317	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013, 260, 2023-2032.	1.8	82
318	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013, 260, 1452-1468.	1.8	189
319	<i>TNFRSF1A</i> polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013, 80, 2010-2016.	1.5	28
320	Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis. <i>Trends in Molecular Medicine</i> , 2013, 19, 157-164.	3.5	40
321	Inhibition of delta-like ligand 4 decreases Th1/Th17 response in a mouse model of multiple sclerosis. <i>Neuroscience Letters</i> , 2013, 541, 161-166.	1.0	22
322	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 742-748.	1.4	35
323	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1082-1091.	0.9	267
324	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1175-1181.	1.4	93

#	ARTICLE	IF	CITATIONS
325	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	1.4	87
326	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013, 136, 1778-1782.	3.7	60
327	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 2167-2175.	6.3	269
328	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 263, 152-154.	1.1	13
329	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013, 12, 756-767.	4.9	205
330	Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 993-994.	1.4	0
331	Identification of a functional variant in the <i>KIF5A-CYP27B1-METTL1-FAM119B</i> locus associated with multiple sclerosis. <i>Journal of Medical Genetics</i> , 2013, 50, 25-33.	1.5	59
332	Genome-wide significant association of ANKRD5 rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013, 50, 140-143.	1.5	34
333	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: No. <i>Multiple Sclerosis Journal</i> , 2013, 19, 717-718.	1.4	6
334	Serum Biomarker gMS-Classifer2: Predicting Conversion to Clinically Definite Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e59953.	1.1	5
335	Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta. <i>PLoS ONE</i> , 2013, 8, e60994.	1.1	27
336	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. <i>PLoS ONE</i> , 2013, 8, e82796.	1.1	23
337	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CLBL genes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 959-965.	1.4	28
338	Olfactory dysfunction in multiple sclerosis: association with secondary progression. <i>Multiple Sclerosis Journal</i> , 2012, 18, 616-621.	1.4	52
339	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2012, 8, 13-21.	4.9	67
340	Subcutaneous alemtuzumab for multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 423-426.	1.3	2
341	EBV-specific immune responses in patients with multiple sclerosis responding to IFN $\beta$ therapy. <i>Multiple Sclerosis Journal</i> , 2012, 18, 605-609.	1.4	20
342	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1466-1471.	1.4	58

#	ARTICLE	IF	CITATIONS
343	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012, 18, 143-152.	1.4	220
344	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2012, 9, 139.	3.1	35
345	Heat Shock Protein 70: Roles in Multiple Sclerosis. <i>Molecular Medicine</i> , 2012, 18, 1018-1028.	1.9	52
346	Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 366, 1000-1009.	13.9	329
347	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1193-1196.	1.4	19
348	DNA-based vaccines for multiple sclerosis: Current status and future directions. <i>Clinical Immunology</i> , 2012, 142, 76-83.	1.4	32
349	Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation. <i>Clinical Immunology</i> , 2012, 142, 84-92.	1.4	24
350	Multiple sclerosis: more pieces of the immunological puzzle. <i>Lancet Neurology</i> , The, 2012, 11, 9-10.	4.9	10
351	Fingolimod for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 131-139.	4.9	72
352	New Insights in the Pathophysiology and Treatment of Multiple Sclerosis Spasticity and Related Symptoms. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1-1.	1.4	2
353	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011, 476, 214-219.	13.7	2,400
354	THC and CBD oromucosal spray (Sativex <sup>®</sup> ) in the management of spasticity associated with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 627-637.	1.4	82
355	Review of methodological issues of clinical trials in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011, 311, S35-S42.	0.3	19
356	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011, 24, 230-237.	1.8	65
357	Tumor necrosis factor alpha (TNF- $\alpha$ ), anti-TNF- $\alpha$ and demyelination revisited: An ongoing story. <i>Journal of Neuroimmunology</i> , 2011, 234, 1-6.	1.1	109
358	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529.	4.9	204
359	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
360	Implication of the toll-like receptor 4 pathway in the response to interferon- $\beta$ in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 70, 634-645.	2.8	35

#	ARTICLE	IF	CITATIONS
361	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011, 134, 693-703.	3.7	96
362	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 319-326.	1.4	11
363	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 351-362.	1.4	23
364	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. <i>Archives of Neurology</i> , 2011, 68, 1421.	4.9	44
365	Search for Specific Biomarkers of IFN $\gamma$ Bioactivity in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e23634.	1.1	45
366	Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. <i>Lancet Neurology</i> , The, 2010, 9, 381-390.	4.9	294
367	B cell expression of the inhibitory Fc $\gamma$ 3 receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010, 223, 135-137.	1.1	5
368	Orchestrating innate immune responses in multiple sclerosis: Molecular players. <i>Journal of Neuroimmunology</i> , 2010, 225, 5-12.	1.1	20
369	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 409-411.	2.8	40
370	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 402-415.	13.9	1,983
371	Targeting dendritic cells to treat multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 499-507.	4.9	61
372	Fingolimod for relapsing multiple sclerosis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1183-1196.	0.9	19
373	Gender-Associated Differences of Perforin Polymorphisms in the Susceptibility to Multiple Sclerosis. <i>Journal of Immunology</i> , 2010, 185, 5392-5404.	0.4	27
374	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010, 133, 1082-1093.	3.7	240
375	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 159-169.	2.8	181
376	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009, 5, 553-560.	4.9	114
377	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 587-92.	4.9	114
378	Tolerance Induction in Experimental Autoimmune Encephalomyelitis Using Non-myeloablative Hematopoietic Gene Therapy With Autoantigen. <i>Molecular Therapy</i> , 2009, 17, 897-905.	3.7	26

#	ARTICLE	IF	CITATIONS
379	Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study. Archives of Neurology, 2009, 66, 1345-52.	4.9	32
380	Genome-wide Scan of 500,000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2009, 66, 972-8.	4.9	104
381	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Multiple Sclerosis Journal, 2009, 15, 1303-1310.	1.4	57
382	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clinical Immunology, 2009, 130, 145-150.	1.4	41
383	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. Clinical Immunology, 2009, 133, 364-374.	1.4	16
384	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, The, 2009, 8, 987-997.	4.9	322
385	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. Human Brain Mapping, 2009, 30, 2412-2425.	1.9	51
386	Early treatment: PreCISE-ly what the patient needs. Journal of the Neurological Sciences, 2009, 287, S2-S6.	0.3	3
387	Multiple sclerosis therapy: historical and future perspectives. Current Opinion in Neurology, 2009, 22, S1-S3.	1.8	1
388	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology, 2008, 255, 480-487.	1.8	63
389	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 2008, 255, 683-691.	1.8	65
390	Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. Annals of Neurology, 2008, 63, 790-793.	2.8	101
391	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	2.8	80
392	Immunotherapy for neurological diseases. Clinical Immunology, 2008, 128, 294-305.	1.4	51
393	FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Review of Neurotherapeutics, 2008, 8, 699-714.	1.4	41
394	Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis. Archives of Neurology, 2008, 65, 337-44.	4.9	154
395	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 455-464.	1.4	58
396	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 412-414.	1.4	6

#	ARTICLE	IF	CITATIONS
397	mtDNA nt13708A Variant Increases the Risk of Multiple Sclerosis. PLoS ONE, 2008, 3, e1530.	1.1	64
398	Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms. PLoS ONE, 2008, 3, e3490.	1.1	99
399	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10.	0.4	3
400	Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study. Archives of Neurology, 2007, 64, 1292.	4.9	46
401	Antimyelin Antibodies with No Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 426-428.	13.9	50
402	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet, The, 2007, 370, 389-397.	6.3	468
403	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 371-378.	13.9	236
404	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology, The, 2007, 6, 677-686.	4.9	292
405	Interferon beta in secondary progressive multiple sclerosis. Journal of Neurology, 2007, 254, 849-853.	1.8	4
406	Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 355, 1124-1140.	13.9	996
407	The value of animal models for drug development in multiple sclerosis. Brain, 2006, 129, 1940-1952.	3.7	133
408	TNF $\alpha$ converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. Journal of Neurology, 2006, 253, 701-706.	1.8	17
409	The importance of long-term data in multiple sclerosis. Journal of Neurology, 2006, 253, vi9-vi15.	1.8	11
410	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurology, The, 2006, 5, 221-227.	4.9	112
411	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurology, The, 2006, 5, 841-852.	4.9	217
412	Altered maturation of circulating dendritic cells in primary progressive MS patients. Journal of Neuroimmunology, 2006, 175, 183-191.	1.1	37
413	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. Journal of Neuroimmunology, 2006, 180, 147-158.	1.1	15
414	Defining the response to interferon $\beta$ in relapsing&remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	2.8	295



#	ARTICLE	IF	CITATIONS
415	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , 2006, 15, 2813-2824.	1.4	279
416	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. <i>Multiple Sclerosis Journal</i> , 2006, 12, 487-494.	1.4	67
417	Primary progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2005, 18, 261-266.	1.8	37
418	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology</i> , The, 2005, 4, 281-288.	4.9	513
419	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , The, 2005, 4, 341-348.	4.9	129
420	Plasma osteopontin levels in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 158, 231-239.	1.1	171
421	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 164, 140-147.	1.1	26
422	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005, 57, 210-215.	2.8	108
423	Interferon beta in relapsing/remitting multiple sclerosis. <i>Journal of Neurology</i> , 2005, 252, 795-800.	1.8	59
424	Interferon- $\beta$ 1b in the treatment of multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2877-2886.	0.9	14
425	Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 306-309.	1.4	184
426	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. <i>Bioinformatics</i> , 2005, 21, ii180-ii181.	1.8	6
427	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004, 10, 618-620.	1.4	9
428	Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, S62-S64.	1.4	31
429	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 413-416.	1.4	30
430	Clinical characteristics of responders to interferon therapy for relapsing MS. <i>Neurology</i> , 2004, 62, 1653-1653.	1.5	26
431	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. <i>Archives of Neurology</i> , 2004, 61, 222.	4.9	32
432	Transcription-Based Prediction of Response to IFN $\beta$ Using Supervised Computational Methods. <i>PLoS Biology</i> , 2004, 3, e2.	2.6	144

#	ARTICLE	IF	CITATIONS
433	The pros and cons of early treatment of relapsing forms of multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, IV30-4.	1.8	7
434	Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10 Suppl 1, S62; discussion 62-4.	1.4	7
435	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. <i>Journal of Neurology</i> , 2003, 250, 243-244.	1.8	4
436	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. <i>Journal of Neuroimmunology</i> , 2003, 143, 124-128.	1.1	35
437	Unconventional therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 320-322.	1.4	18
438	Serial immunoprecipitation assays for interferon- $\gamma$ (IFN)-beta antibodies in multiple sclerosis patients. <i>European Cytokine Network</i> , 2003, 14, 154-7.	1.1	9
439	Interferon- $\gamma$ Regulates Oxidative Stress during Experimental Autoimmune Encephalomyelitis. <i>Experimental Neurology</i> , 2002, 177, 21-31.	2.0	22
440	Specific Proliferation Towards Myelin Antigens in Patients with Multiple Sclerosis During a Relapse. <i>Autoimmunity</i> , 2002, 35, 45-50.	1.2	19
441	The proteasome is a major autoantigen in multiple sclerosis. <i>Brain</i> , 2002, 125, 2658-2667.	3.7	48
442	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon- $\gamma$ . <i>Journal of Neuroimmunology</i> , 2002, 130, 194-201.	1.1	78
443	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon $\gamma$ : Implications for clinical trials. <i>Annals of Neurology</i> , 2002, 52, 400-406.	2.8	114
444	Serial proton spectroscopy, magnetization transfer ratio and T2 relaxation in pseudotumoral demyelinating lesions. <i>NMR in Biomedicine</i> , 2002, 15, 284-292.	1.6	11
445	Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. <i>Journal of Neurology</i> , 2002, 249, 1063-1065.	1.8	38
446	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. <i>American Journal of Neuroradiology</i> , 2002, 23, 989-94.	1.2	56
447	Treatment with Anti-interferon- $\gamma$ Monoclonal Antibodies Modifies Experimental Autoimmune Encephalomyelitis in Interferon- $\gamma$ Receptor Knockout Mice. <i>Experimental Neurology</i> , 2001, 172, 460-468.	2.0	30
448	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001, 49, 408-411.	2.8	42
449	Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001, 119, 248-260.	1.1	70
450	Frequency of Multiple Sclerosis in Menorca, Balearic Islands, Spain. <i>Neuroepidemiology</i> , 2001, 20, 129-133.	1.1	31

#	ARTICLE	IF	CITATIONS
451	Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR in Biomedicine, 2000, 13, 57-63.	1.6	41
452	CD4+CD45RO+CD49dhhigh cells are involved in the pathogenesis of relapsingâ€“remitting multiple sclerosis. Journal of Neuroimmunology, 2000, 111, 215-223.	1.1	26
453	Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. Journal of Neuroimmunology, 1998, 84, 24-29.	1.1	8
454	Daclizumab to treat multiple sclerosis. , 0, , 399-404.		0